Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191941 | 1.00 | USP2 (0.44) | USP2SMN1; SMN2GPR119NR1H2HSD17B10 | |
| SCHEMBL28303686 | 1.00 | USP2 (0.44) | USP2SMN1; SMN2GPR119NR1H2HSD17B10 | |
| SCHEMBL1536052 | 0.98 | USP2 (0.42) | USP2SMN1; SMN2GPR119NR1H2HSD17B10 | |
| SCHEMBL3564440 | 0.86 | USP2 (0.42) | USP2SMN1; SMN2GPR119NR1H2MMP1 | |
| SCHEMBL12524861 | 0.86 | USP2 (0.42) | USP2SMN1; SMN2GPR119NR1H2MMP1 | |
| Lithium Ion SCHEMBL1536049 | 0.84 | MMP1 (0.42) | USP2SMN1; SMN2GPR119NR1H2USP30 | |
| SCHEMBL30289256 | 0.84 | MMP1 (0.45) | USP2SMN1; SMN2NR1H2MMP1MMP3 | |
| SCHEMBL1536817 | 0.84 | MMP1 (0.45) | USP2SMN1; SMN2NR1H2MMP1MMP3 | |
| SCHEMBL1536816 | 0.84 | MMP1 (0.45) | USP2SMN1; SMN2NR1H2MMP1MMP3 | |
| SCHEMBL22227 | 0.84 | HSD17B10 (0.51) | USP2SMN1; SMN2GPR119NR1H2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368625-A1 | PIPERAZINES | Grünenthal GmbH (DE) | 2025-12-04 | — | — | US | disclosed |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | disclosed |
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2018-10-11 | — | — | US | disclosed |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| EP-3031324-A2 | TRICYCLIC KINASE INHIBITORS | AbbVie Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-3031324-A2 | TRICYCLIC KINASE INHIBITORS | AbbVie Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9365579-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365579-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2299821-B1 | TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2299821-B1 | TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150210708-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210708-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-8962629-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962629-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20090312338-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009152133-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152133-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | USP2 4824/4885SMN1; SMN2 3236/4885GPR119 1201/4885 |
| US-20090312338-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | USP2 4824/4885SMN1; SMN2 3236/4885GPR119 1201/4885 |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | USP2 4824/4885SMN1; SMN2 3236/4885GPR119 1201/4885 |
| US-20150210708-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | USP2 4824/4885SMN1; SMN2 3236/4885GPR119 1201/4885 |
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | USP2 4508/4885SMN1; SMN2 4280/4885GPR119 823/4885 |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | USP2 4824/4885SMN1; SMN2 3236/4885GPR119 1201/4885 |
| US-20250368625-A1 | PIPERAZINES | SSTR4, SSTR5, SSTR2 | USP2 3521/4885SMN1; SMN2 1255/4885GPR119 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.